Literature DB >> 19646206

Immunopathogenic competences of Leishmania (V.) braziliensis and L. (L.) amazonensis in American cutaneous leishmaniasis.

F T Silveira1, R Lainson, C M De Castro Gomes, M D Laurenti, C E P Corbett.   

Abstract

The immunopathogenic competences of Leishmania (V.) braziliensis and L. (L.) amazonensis were reviewed in the light of more recent features found in the clinical and immunopathological spectrum of American cutaneous leishmaniasis. It was shown a dichotomy in the interaction between these Leishmania species and human T-cell immune response; while L. (V.) braziliensis shows a clear tendency to lead infection from the localized cutaneous leishmaniasis (LCL), a moderate T-cell hypersensitivity form at the centre of the spectrum, toward to the mucocutaneous leishmaniasis (MCL) at the T-cell hypersensitivity pole and with a prominent Th1-type immune response, L. (L.) amazonensis shows an opposite tendency, leading infection to the anergic diffuse cutaneous leishmaniasis (ADCL) at the T-cell hyposensitivity pole and with a marked Th2-type immune response. Between the central LCL and the two polar MCL and ADCL, the infection can present an intermediary form known as borderline disseminated cutaneous leishmaniasis, characterized by an incomplete inhibition of T-cell hypersensitivity but with a evident supremacy of Th1 over Th2 immune response (Th1 > or = Th2). These are probably the main immunopathogenic competences of L. (V.) braziliensis and L. (L.) amazonensis regarding the immune response dichotomy that modulates human infection outcome by these Leishmania parasites.

Entities:  

Mesh:

Year:  2009        PMID: 19646206     DOI: 10.1111/j.1365-3024.2009.01116.x

Source DB:  PubMed          Journal:  Parasite Immunol        ISSN: 0141-9838            Impact factor:   2.280


  66 in total

1.  Leishmania (Viannia) shawi purified antigens confer protection against murine cutaneous leishmaniasis.

Authors:  Luiz Felipe Domingues Passero; Ana Kely Carvalho; Maria Luiza A C Bordon; Alexis Bonfim-Melo; Marcos Hikari Toyama; Carlos Eduardo Pereira Corbett; Márcia Dalastra Laurenti
Journal:  Inflamm Res       Date:  2011-12-14       Impact factor: 4.575

2.  Multifunctional CD4⁺ T cells in patients with American cutaneous leishmaniasis.

Authors:  A B B Macedo; J C Sánchez-Arcila; A O Schubach; S C F Mendonça; A Marins-Dos-Santos; M de Fatima Madeira; T Gagini; M I F Pimentel; P M De Luca
Journal:  Clin Exp Immunol       Date:  2012-03       Impact factor: 4.330

3.  Treatment with triterpenic fraction purified from Baccharis uncinella leaves inhibits Leishmania (Leishmania) amazonensis spreading and improves Th1 immune response in infected mice.

Authors:  Eduardo Seiji Yamamoto; Bruno Luiz S Campos; Márcia Dalastra Laurenti; João H G Lago; Simone dos Santos Grecco; Carlos E P Corbett; Luiz Felipe D Passero
Journal:  Parasitol Res       Date:  2013-10-31       Impact factor: 2.289

4.  Comparative genomics of canine-isolated Leishmania (Leishmania) amazonensis from an endemic focus of visceral leishmaniasis in Governador Valadares, southeastern Brazil.

Authors:  Hugo O Valdivia; Laila V Almeida; Bruno M Roatt; João Luís Reis-Cunha; Agnes Antônia Sampaio Pereira; Celia Gontijo; Ricardo Toshio Fujiwara; Alexandre B Reis; Mandy J Sanders; James A Cotton; Daniella C Bartholomeu
Journal:  Sci Rep       Date:  2017-01-16       Impact factor: 4.379

Review 5.  Immunopathogenesis of non-healing American cutaneous leishmaniasis and progressive visceral leishmaniasis.

Authors:  Lynn Soong; Calvin A Henard; Peter C Melby
Journal:  Semin Immunopathol       Date:  2012-10-11       Impact factor: 9.623

6.  Intralesional uridine-5'-triphosphate (UTP) treatment induced resistance to Leishmania amazonensis infection by boosting Th1 immune responses and reactive oxygen species production.

Authors:  Camila Marques-da-Silva; Mariana M Chaves; Maria Luiza Thorstenberg; Vanessa R Figliuolo; Flávia S Vieira; Suzana P Chaves; José Roberto Meyer-Fernandes; Bartira Rossi-Bergmann; Luiz Eduardo Baggio Savio; Robson Coutinho-Silva
Journal:  Purinergic Signal       Date:  2018-04-21       Impact factor: 3.765

7.  Impaired Th1 Response Is Associated With Therapeutic Failure in Patients With Cutaneous Leishmaniasis Caused by Leishmania braziliensis.

Authors:  Augusto M Carvalho; Luiz H Guimarães; Rúbia Costa; Maíra G Saldanha; Iana Prates; Lucas P Carvalho; Sérgio Arruda; Edgar M Carvalho
Journal:  J Infect Dis       Date:  2021-02-13       Impact factor: 5.226

8.  Histopathological features of skin lesions in patients affected by non-ulcerated or atypical cutaneous leishmaniasis in Honduras, Central America.

Authors:  Carmen Maria Sandoval Pacheco; Gabriela Venicia Araujo Flores; Aurea Favero Ferreira; Wilfredo Sosa Ochoa; Vânia Lúcia Ribeiro da Matta; Concepción Zúniga Valeriano; Carlos Eduardo Pereira Corbett; Marcia Dalastra Laurenti
Journal:  Int J Exp Pathol       Date:  2018-11-27       Impact factor: 1.925

9.  Biochemical changes in Leishmania braziliensis after photodynamic therapy with methylene blue assessed by the Fourier transform infrared spectroscopy.

Authors:  Kumiko Koibuchi Sakane; Tanmoy Bhattacharjee; Jaciara Fagundes; Luciana Maria Cortez Marcolino; Isabelle Ferreira; Juliana Guerra Pinto; Juliana Ferreira-Strixino
Journal:  Lasers Med Sci       Date:  2020-08-03       Impact factor: 3.161

10.  Real-time PCR assay for detection and quantification of Leishmania (Viannia) organisms in skin and mucosal lesions: exploratory study of parasite load and clinical parameters.

Authors:  Marlene Jara; Vanessa Adaui; Braulio M Valencia; Dalila Martinez; Milena Alba; Carlos Castrillon; Maria Cruz; Israel Cruz; Gert Van der Auwera; Alejandro Llanos-Cuentas; Jean-Claude Dujardin; Jorge Arevalo
Journal:  J Clin Microbiol       Date:  2013-04-03       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.